Guoping Ou

Dr. Guoping Ou


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
XLXiaohua Liu
Xiaohua Liu
LSLili Su
Lili Su
JLJingcong Li
Jingcong Li
GOGuoping Ou
Guoping Ou
The poor performance of single-gene lists for prognostic predictions in independent cohorts has limited their clinical use. Here, we employed a pathway-based approach using embedded biological features to identify reproducible prognostic markers as an alternative. We used pathway activity score, sure independence screening, and K-means clustering analyses to identify and cluster colorectal cancer patients into two distinct subgroups, G2 (aggressive) and G1 (moderate). The differences between these two groups with respect to survival, somatic mutation, pathway activity, and tumor-infiltration by immunocytes were compared. These comparisons revealed that the survival rates in the G2 subgroup were significantly reduced compared to that in the G1 subgroup; further, the mutational burden rates in several oncogenes, including KRAS, DCLK1, and EPHA5, were significantly higher in the G2 subgroup than in the G1 subgroup. The enhanced activity of the critical pathways such as MYC and epithelial-mesenchymal transition may also lead to the progression of colorectal cancer. Taken together, we established a novel prognostic classification system that offers meritorious insights into the hallmarks of colorectal cancer.

9 December 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
GOGuoping Ou
Guoping Ou
QCQiaolun Chen
Qiaolun Chen
WLWanli Liu
Wanli Liu
XLXiaohui Li
Xiaohui Li
SCShulin Chen
Shulin Chen
HCHao Chen
Hao Chen

1 July 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GOGuoping Ou
Guoping Ou
JGJuhua Gou
Juhua Gou
HOHongmu Ou
Hongmu Ou
HZHailin Zheng
Hailin Zheng
YZYuanying Zhu
Yuanying Zhu
XLXiaohua Liu
Xiaohua Liu
This project aimed to discover independent gut markers of immunotherapy based on qPCR method. 80 metastatic melanoma patients receiving immunotherapy were enrolled in this study, and the relative abundance of 41 gut markers was worked out by a newly established qPCR method. The HR of these gut markers was calculated using Rstudio-coxph. The associations between these 41 gut markers and age as well as treatment-course were analyzed by heatmap, linear-regression or VIF. Markers for Cox prediction model were selected according to the results of HR, VIF and LASSO regression. Nomogram, calibration curves for nomogram and stratified survival analysis were used to observe the predictive performance of the prediction model and related gut markers. BloUP may be associated with pseudoresponse of immunotherapy, especially in elderly patients. Age (risk**), treatment-type*, treatment-course (protective), clinical-response**, LDH (risk), Amc (risk**), Bvu (protective), Cpe (protective) and Rgn (risk) were recommended as predictors of immunotherapy. For patients with Age> 55 or LDH> 196, the detection of Amc could further predict the prognosis (p = 0.065, p = 0.013). For patients with Age< 55 or LDH< 196, the detection of Bvu could further predict the prognosis (p = 0.007, p = 0.011). For patients with Amc< 0.76 or Bvu > 0.84, longer treatment duration (treatment-course> 10) will significantly improve prognosis (p < 0.001, p = 0.007). AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, the detection of Amc and Bvu may had potential impacts on immunotherapy strategies. Further detection of gut markers (Amc and Bvu) could better predict patients’ responsiveness to immunotherapy. Revealed the predictive power of 41 gut markers in immunotherapy. Proposed that BloUP may be associated with pseudoresponse in elderly patients. Recommended Amc and Bvu as independent predictive markers of immunotherapy. Proposed that AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, and the detection of Amc and Bvu may had potential impacts on immunotherapy strategies.

1 January 2020 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
PDF file
SXShan Xing
Shan Xing
HLHuilan Li
Huilan Li
YPYingqi Pi
Yingqi Pi
TZTao Zeng
Tao Zeng
QHQi Huang
Qi Huang
NXNing Xue
Ning Xue
We evaluated the diagnostic value of plasma Macrophage inhibitory cytokine-1 (MIC-1) in distinguishing patients with nasopharyngeal carcinoma (NPC) and explored its complementary role with widely used Epstein-Barr virus (EBV) related markers, EBV capsid antigen-specific IgA (VCA-IgA) and EBV copy number. ELISA was used to analyze the plasma MIC-1 levels in 190 NPC patients, 72 VCA-IgA-positive healthy donors (VP), and 219 normal subjects with negative VCA-IgA (VN). 10 pairs of plasma samples before and after radiotherapy were also included. The plasma MIC-1 levels were significantly higher in NPC patients (Median: 678.39 ng/mL) than those in VN and VP (310.29 and 294.59, p < 0.001). Receiver operating characteristic (ROC) curves of the MIC-1 concentrations revealed that the area under the ROC curve (AUC) was 0.790 (95% confidence interval [CI]: 0.748-0.832), with a sensitivity of 63.7%, and a specificity of 85.9% respectively, for distinguishing NPC patients from the healthy donors. Similarly, between NPC and VP, ROC was 0.796 (0.738-0.853) with sensitivity of 63.7%, and specificity of 88.9%. In addition, between NPC and VN, ROC was 0.788(0.744-0.832) with sensitivity of 63.7%, and specificity of 84.9%. Further, we found that MIC-1 could complement VCA-IgA and EBV DNA markers, with a negative rate of 88.9% in VCA-IgA-positive healthy controls, and a positive rate of 59.0% in EBV DNA negative NPC patients, respectively. Also, the MIC-1 plasma concentration dropped significantly after radiotherapy (p = 0.027). MIC-1 can complement VCA-IgA titers and EBV DNA copy number tests in NPC detection, improve identification of EBV DNA-negative NPC patients, and distinguish NPC from VCA -IgA positive healthy controls.

21 October 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
XLXiaohua Liu
Xiaohua Liu
LSLili Su
Lili Su
JLJingcong Li
Jingcong Li
GOGuoping Ou
Guoping Ou
Recently, many studies have investigated the role of gene-signature on the prognostic assessment of breast cancer (BC), however, the tumor heterogeneity and sequencing noise have limited the clinical usage of these models. Pathway-based approaches are more stable to the perturbation of certain gene expression. In this study, we constructed a prognostic classifier based on survival-related pathway crosstalk analysis. We estimated pathway’s deregulation scores (PDSs) for samples collected from public databases to select survival-related pathways. After pathway crosstalk analysis, we conducted K-means clustering analysis to cluster the patients into G1 and G2 subgroups. The survival outcome of the G2 subgroup was significantly worse than the G1 subgroup. Internal and external dataset exhibits high consistency with the training dataset. Significant differences were found between G2 and G1 subgroups on pathway activity, gene mutation, immune cell infiltration levels, and in particular immune cells/pathway’s activities were significantly negatively associated with BC patient’s outcomes. In conclusion, we established a novel classifier reflecting the overall survival risk of BC and successfully validated its clinical usage on multiple BC datasets, which could offer clinicians inspiration in formulating the clinical treatment plan.